Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
In brief
Ten Asian oncology societies align kidney cancer guidance with global and regional evidence
Experts from 10 Asian countries adapted European guidance for kidney cancer, using evidence from both Western and Asian trials to support more consistent care across the region. The recommendations were based on scientific evidence, not local drug access or reimbursement; differences in approvals and coverage remain a practical barrier to applying them uniformly.
- Journal
- ESMO open (Q1)
- Published
- 1 October 2026
- Study design
- Practice guideline / consensus
- Evidence level
- Level 1, High (CEBM 1c)
- Authors
- R Kanesvaran, V Gruenwald, A Wong, J Chan, X Yaoi, N A Mulansari, et al.
- PMID
- 42914499
- DOI
- 10.1016/j.esmoop.2026.108552
Why clinicians should know about it
- Picked for Urology (top studies of the week, 25 October 2026): Adapted clinical practice guidelines for renal cell carcinoma
Abstract
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma (RCC) were published in May 2024 and adapted in December 2025 according to previously established standard methodology to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with RCC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with RCC representing the oncological societies of China [Chinese Society of Clinical Oncology (CSCO)], Indonesia [Indonesian Society of Hematology and Medical Oncology (ISHMO)], India [Indian Society of Medical and Paediatric Oncology (ISMPO)], Japan [Japanese Society of Medical Oncology (JSMO)], Korea [Korean Society of Medical Oncology (KSMO)], Malaysia [Malaysian Oncological Society (MOS)], The Philippines [Philippine Society of Medical Oncology (PSMO)], Singapore [Singapore Society of Oncology (SSO)], Taiwan [Taiwan Oncology Society (TOS)] and Thailand [Thai Society of Clinical Oncology (TSMO)], coordinated by ESMO and the SSO. The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with RCC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in drug approvals and reimbursement strategies between the different regions.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.